Seoul [South Korea], February 9 (ANI/Global Economic): As the Omicron COVID-19 variant, which is now the most dominant strain in the world, rapidly spread in Korea, SK Bioscience also started developing Omicron-specific vaccines.
As the Omicron COVID-19 variant, which is now the most dominant strain in the world, rapidly spread in Korea, SK Bioscience also started developing Omicron-spec
Moderna, an American pharmaceutical and biotechnology company based in Cambridge on Wednesday (local time) announced that it has begun clinical trials of a booster dose of a vaccine designed specifically to combat the Omicron variant of COVID-19.
Pfizer Opens Study of Omicron Specific COVID-19 Shot 9and10news.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 9and10news.com Daily Mail and Mail on Sunday newspapers.